logo
GEHealthCareAnnouncesFirstPatientDosedinPhase2/3LUMINATrialforManganese-BasedMRIContrastAgentUnderFDAFastTrackDesignation,FurtherAdvancingItsInnovationPipelineofNovelImagingAgents
===2026/4/24 10:39:04===
1370
david.j.morris@gehealthcare.com



First-in-human contrast enhanced MRI images with GE HealthCares mangaciclanol
=*=*=*=*=*=
当前为第7/7页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页